Prevalence and Outcome of Secondary Hemophagocytic Lymphohistiocytosis Among SIRS Patients: Results from a Prospective Cohort Study
- PMID: 31010216
- PMCID: PMC6518152
- DOI: 10.3390/jcm8040541
Prevalence and Outcome of Secondary Hemophagocytic Lymphohistiocytosis Among SIRS Patients: Results from a Prospective Cohort Study
Abstract
Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening condition clinically presenting as SIRS (Systemic Inflammatory Response Syndrome). However, there is no comprehensive data concerning diagnostic algorithms, prevalence, outcome and biomarker performance in SIRS patients. We conducted a prospective observational cohort study on 451 consecutive patients fulfilling ≥2 SIRS criteria. The Hscore and the HLH-2004 criteria were used to determine the presence of sHLH, and the correlation of the screening-biomarkers ferritin, sCD25, and sCD163 with both scores was assessed. Out of 451 standard-care SIRS patients, five patients had high Hscores (≥169), suggesting incipient or HLH-like disease, and these patients were in urgent need for intensified therapy. However, none of these patients fulfilled five HLH-2004 criteria required for formal diagnosis. From the studied biomarkers, ferritin correlated strongest to both the HLH-2004 criteria and the Hscore (rs = 0.72, 0.41, respectively), and was the best predictor of 30-day survival (HR:1.012 per 100 μg/L, 95% CI: 1.004-1.021), when adjusted for patient's age, sex, bacteremia and malignant underlying-disease. Also, the HLH-2004 (HR per point increase: 1.435, 95% CI: 1.1012-2.086) and the Hscore (HR per point increase:1.011, 95% CI: 1.002-1.020) were independent predictors of 30-day-survival. The Hscore detected patients in hyperinflammatory states requiring urgent therapy escalation. Degrees of hyperinflammation, as assessed by ferritin and both HLH scores, are associated with worse outcomes.
Keywords: HLH; SIRS; hemophagocytic lymphohistiocytosis; hemophagocytosis; outcome; prevalence; survival.
Conflict of interest statement
All authors declare that they have no conflict of interest.
Figures



Similar articles
-
Prognostic Factors of Adult Hemophagocytic Lymphohistiocytosis and Clinical Utility of HLH-2004 Diagnostic Criteria and HScore: A Real-World Multicenter Study from Thailand.Acta Haematol. 2024;147(4):447-456. doi: 10.1159/000536287. Epub 2024 Jan 23. Acta Haematol. 2024. PMID: 38262370
-
Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore.Crit Care. 2020 May 24;24(1):244. doi: 10.1186/s13054-020-02941-3. Crit Care. 2020. PMID: 32448380 Free PMC article.
-
Value of hemophagocytosis in the diagnosis of hemophagocytic lymphohistiocytosis in critically ill patients.Eur J Haematol. 2024 Jun;112(6):917-926. doi: 10.1111/ejh.14185. Epub 2024 Feb 18. Eur J Haematol. 2024. PMID: 38368850
-
[Secondary hemophagocytic lymphohistiocytosis and cytokine release syndrome in COVID-19, the same or different entities?].Rev Chilena Infectol. 2021 Apr;38(2):271-278. doi: 10.4067/S0716-10182021000200271. Rev Chilena Infectol. 2021. PMID: 34184718 Review. Spanish.
-
[Hemophagocytic lymphohistiocytosis: diagnostic problems in pediatrics].Przegl Lek. 2010;67(6):417-24. Przegl Lek. 2010. PMID: 21344773 Review. Polish.
Cited by
-
Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.Ann Med. 2023 Dec;55(1):89-100. doi: 10.1080/07853890.2022.2149850. Ann Med. 2023. PMID: 36533966 Free PMC article.
-
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP).Front Immunol. 2020 Mar 31;11:524. doi: 10.3389/fimmu.2020.00524. eCollection 2020. Front Immunol. 2020. PMID: 32296434 Free PMC article. Review.
-
Development of a Nomogram for Predicting Massive Necrotizing Pneumonia in Children.Infect Drug Resist. 2023 Mar 29;16:1829-1838. doi: 10.2147/IDR.S408198. eCollection 2023. Infect Drug Resist. 2023. PMID: 37016631 Free PMC article.
-
Clinical Profile, Treatment, and Outcome of Patients with Secondary Hemophagocytic Lymphohistiocytosis in Critically Ill Patients: A Prospective Observational Study.Indian J Crit Care Med. 2022 May;26(5):564-567. doi: 10.5005/jp-journals-10071-24136. Indian J Crit Care Med. 2022. PMID: 35719456 Free PMC article.
-
Utility of the HScore for Predicting COVID-19 Severity.Cureus. 2022 Nov 28;14(11):e31969. doi: 10.7759/cureus.31969. eCollection 2022 Nov. Cureus. 2022. PMID: 36589196 Free PMC article.
References
-
- Kleynberg R.L., Schiller G.J. Secondary hemophagocytic lymphohistiocytosis in adults: An update on diagnosis and therapy. Clin. Adv. Hematol. Oncol. 2012;10:726–732. - PubMed
LinkOut - more resources
Full Text Sources